What Sarcomatrix does

Sarcomatrix is a clinical-stage biopharmaceutical company developing novel therapeutics for muscle-wasting diseases, with its lead candidate S-969 advancing through IND-enabling studies for Duchenne Muscular Dystrophy (DMD). The company targets the α7β1 integrin pathway (via the Hippo-YAP mechanism to upregulate integrin expression) and laminin pathways for muscle regeneration, differentiating its small-molecule approach from competing gene therapies and dystrophin-replacement strategies. Its pipeline includes S-969 as an oral small molecule for DMD, Becker Muscular Dystrophy, sarcopenia, and cachexia, plus rhLAM-111 (recombinant human laminin-111) for LAMA2-Related Muscular Dystrophy (LAMA2-RD), acquired from Prothelia in March 2023. Supporting the pipeline are two proprietary platforms: SarcoScreen, a high-throughput functional screening platform for muscle cell assays, and SarcoVista, an AI-driven translational platform that integrates proprietary large animal and non-human primate datasets into predictive models for clinical dose selection and trial design.

The company operates through an exclusive research partnership with Strykagen (a University of Nevada, Reno spin-off from the Dean Burkin Lab) and maintains an IP portfolio of over 75 patents covering integrin-activating compounds and laminin protein replacement therapies. Sarcomatrix has secured approximately $8M in NIH grants, a $958,973 SBIR Phase 2 grant (via Strykagen), $300,000 from Nevada's Battle Born Venture program, and is currently raising a $5M Seed+ round under Regulation D 506(c). It holds EU Orphan Drug Designation for rhLAM-111 and is pursuing FDA Orphan Drug, Breakthrough Therapy, Fast Track, and Priority Review designations for S-969.

Sarcomatrix is pre-revenue with no commercial products, targeting U.S. market entry as early as 2028-2029. The business model anticipates future pharmaceutical product sales through traditional distribution channels, with management exploring co-development partnerships, out-licensing of larger indications (sarcopenia, cachexia), or acquisition as potential exit paths. The company serves rare disease patient populations including DMD, Becker Muscular Dystrophy, and LAMA2-RD patients, with an addressable market for muscle-wasting diseases projected at $18 billion by 2030 and DMD specifically at $13 billion by 2033. Customer concentration risk is negligible at present given the pre-commercial stage, though post-launch revenue will depend heavily on orphan drug pricing dynamics and rare disease market access.

Name

Sarcomatrix

Legal name

Sarcomatrix Therapeutics Corp.

Website

https://sarcomatrix.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

Sarcomatrix is a clinical-stage biopharmaceutical company developing oral small molecule and protein replacement therapies targeting the α7β1 integrin and laminin pathways for muscle-wasting diseases including Duchenne Muscular Dystrophy, LAMA2-RD, sarcopenia, and cachexia, targeting U.S. market entry in 2028-2029.

Ownership category

akta.pro rank

Product category

Muscle-Wasting Disease Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)

akta.pro secondary industry

Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)

Keywords

• Muscular dystrophy therapeutics
• Integrin targeted therapy
• Rare disease biopharmaceuticals
• Muscle regeneration drugs
• Protein replacement therapy

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Sales: Pre-revenue company. The company is developing therapies for muscle-wasting diseases with plans to commercialize treatments upon regulatory approval. Target market entry is projected as early as 2028-2029 for DMD treatment.
2. Out-licensing / Co-development Partnerships: The company is exploring potential exit opportunities including co-development partnerships, out-licensing of larger indications such as Cachexia and Sarcopenia, or an outright acquisition.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

Sarcomatrix is a clinical-stage biopharmaceutical company developing novel therapeutics for muscle-wasting diseases by targeting α7β1 integrin and laminin pathways. Its lead candidate S-969 is an oral small molecule that enhances α7 integrin expression via the Hippo-YAP pathway to promote muscle regeneration, and LAM-111 is a recombinant human laminin-111 protein replacement therapy for LAMA2-RD. Programs are supported by the proprietary SarcoScreen™ drug discovery and SarcoVista™ AI-driven translational platforms.

Product overview

Sarcomatrix is a clinical-stage biopharmaceutical company developing a portfolio of muscle disease therapies. The core product is S-969, an oral small molecule targeting the Hippo-YAP pathway to upregulate α7β1 integrin for muscle regeneration. The company also has LAM-111, a recombinant human laminin-111 protein replacement therapy. Supporting these therapeutics are two proprietary platforms: SarcoScreen, a high-throughput drug discovery screening system, and SarcoVista, an AI-driven translational platform for clinical development optimization. The technology approach focuses on targeting α7β1 integrin and laminin pathways to enhance muscle regeneration and repair.

Differentiator

Problem solved

Functional benefit

Brands

• SarcoVista: Proprietary AI-driven translational platform designed to accelerate and optimize clinical development of lead program S-969
• SarcoScreen
• SarcoDYN

Products and services

• S-969 Oral small molecule drug candidate targeting the Hippo-YAP pathway that enhances α7β1 integrin expression to promote muscle regeneration in Duchenne Muscular Dystrophy and other muscle-wasting indications (sarcopenia, cachexia). Currently in IND-enabling stage with pursued FDA Orphan Drug, Breakthrough Therapy, Fast Track, and Priority Review designations.
• LAM-111 (rhLAM-111) Recombinant human laminin-111 protein replacement therapy for LAMA2-Related Muscular Dystrophy (LAMA2-RD), replacing defective laminin to support muscle function. Holds EU Orphan Drug Designation and is also being evaluated for application in Duchenne Muscular Dystrophy.
• SarcoDYN Supplement product combining leucine, vitamin D3, and magnesium formulated for adults at risk of sarcopenia (age-related muscle loss).

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability4 records

Feature4 records

Partnerships

Twelve partnerships are on record, tiered core and minor.

• Celito TechcoreImplementation/ SI/ Consulting Partner · 7 January 2025Strategic collaboration to leverage cutting-edge technology solutions for advancing S-969 into clinical trials. Celito provides its Helyx Platform including Helyx Clinical Suite for clinical trial planning, execution, and analytics, and Helyx Quality Suite for compliance and data integrity. Partnership covers IT, Cybersecurity, Quality, and G&A Infrastructure.
• StrykagencoreStrategic or Co-development PartnerStrykagen is the exclusive research partner for Sarcomatrix, established as a research spin-off from the Dean Burkin Lab at the University of Nevada, Reno. Strykagen holds exclusive development and commercialization rights licensed to Sarcomatrix. The partnership has received SBIR Phase 2 grant funding from NIH ($958,973 of total $1.95M) for IND-enabling studies for S-969.
• University of Nevada, Reno / Dean Burkin LabcoreStrategic or Co-development PartnerCritical foundational partner and originators of Sarcomatrix's extensive research. The Burkin Lab, led by Dean Burkin, is a recognized world expert on the role of integrins and laminin in muscle disease. The lab was the first to show that α7β1 integrin can serve as a surrogate for the loss of dystrophin in DMD.
• Duchenne UKminorOthersPatient support organization collaborating with Sarcomatrix to help inform the design of clinical trials.
• Duchenne AustraliaminorOthersPatient support organization collaborating with Sarcomatrix to help inform the design of clinical trials.
• Cure CMDminorOthersPatient advocacy group partnering with Sarcomatrix to keep the patient community informed and engaged throughout the development process.
• Parent Project Muscular Dystrophy (PPMD)minorOthersPatient advocacy group partnering with Sarcomatrix to keep the patient community informed and engaged throughout the development process.
• Putnam InsightsminorImplementation/ SI/ Consulting PartnerService provider partner for public relations and investor relations support.
• ScendeaminorImplementation/ SI/ Consulting PartnerService provider partner for regulatory and consulting services.
• Texas A&MminorStrategic or Co-development PartnerResearch collaboration for Duchenne muscular dystrophy dog model studies as part of preclinical research program.
• Prothelia, Inc.coreOEM/ Whitelabel/ Licensing PartnerAcquired recombinant human laminin-111 (rhLAM-111) as a potential treatment for LAMA2-Related Dystrophies from Prothelia, Inc. This acquisition delivered new capabilities to enhance muscular dystrophy research activities and strengthened the portfolio.
• Muscular Dystrophy AssociationminorOthersPatient registry partnership for accessing diverse patient populations for clinical trial recruitment.

Scale indicators9 records

Recent moves7 records

Expansion highlights7 records

Broad incumbents

• Scholar Rock: Clinical-stage biotech developing apitegromab (myostatin inhibitor) for SMA and broader muscle disorders. Operates in the muscle biology space with overlapping mechanism interest in muscle regeneration.
• BioMarin Pharmaceutical: Major rare-disease biopharma with a neuromuscular and enzyme-replacement franchise (e.g., Vimizim, Naglazyme). Comparable in its recombinant-protein replacement approach (LAM-111 analog) and rare-disease commercial expertise.
• Catalyst Pharmaceuticals: Specialty pharma focused on rare diseases including LAMA2-RD-adjacent neuromuscular disorders. Comparable as a smaller rare-disease commercial-stage peer with relevant patient advocacy and orphan-drug expertise.

Direct peers

• Sarepta Therapeutics: The dominant DMD franchise with PMO-based Exondys 51, Vyondys 53, Amondys 45, and Elevidys gene therapy. Directly competing in the same Duchenne patient population that Sarcomatrix targets.
• NS Pharma: Subsidiary of Nippon Shinyaku developing Viltepso (viltolarsen) for DMD. Direct competitor in the Duchenne treatment space with an approved exon-skipping therapy.
• PepGen: Clinical-stage company developing enhanced delivery oligonucleotides for DMD and DM1. Targets the same Duchenne population with a different modality, competing for the same patient pool and partnership attention.
• Edgewise Therapeutics: Clinical-stage biotech developing oral small molecules for muscle diseases including Duchenne (EDG-5506) and Becker muscular dystrophy. Closest direct comparable given shared focus on mutation-agnostic, oral small-molecule approaches in muscle-wasting diseases.
• Solid Biosciences: Gene therapy developer focused on DMD (SGT-001) and other neuromuscular diseases. Direct competitor for Duchenne market share with a different but overlapping therapeutic modality.
• PTC Therapeutics: Markets Translarna (ataluren) for DMD and has a pipeline in muscular dystrophy and rare disorders. Direct competitor addressing the same Duchenne and Becker muscular dystrophy populations.
• Capricor Therapeutics: Late-stage biotech developing CAP-1002 cell therapy for DMD and BMD. Competes directly for Duchenne patient access and represents an alternative mechanism (cell therapy vs. small molecule) for muscle disease.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/sarcomatrix
• Facebookfacebook.com/sarcomatrix
• LinkedInlinkedin.com/company/sarcomatrix
• Instagraminstagram.com/sarcomatrix1

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sarcomatrix